WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406838
CAS#: 865783-95-5
Description: ON-013100 is a cell cycle inhibitor and is potentially useful for the treatment of mantle cell lymphoma.
MedKoo Cat#: 406838
Name: ON-013100
CAS#: 865783-95-5
Chemical Formula: C19H22O7S
Exact Mass: 394.1086
Molecular Weight: 394.438
Elemental Analysis: C, 57.86; H, 5.62; O, 28.39; S, 8.13
Synonym: ON-013100; ON 013100; ON013100.
IUPAC/Chemical Name: (E)-5-(((2,4,6-Trimethoxystyryl)sulfonyl)methyl)-2-methoxyphenol
InChi Key: GHPUSRLWNSTQIK-BQYQJAHWSA-N
InChi Code: InChI=1S/C19H22O7S/c1-23-14-10-18(25-3)15(19(11-14)26-4)7-8-27(21,22)12-13-5-6-17(24-2)16(20)9-13/h5-11,20H,12H2,1-4H3/b8-7+
SMILES Code: OC1=CC(CS(=O)(/C=C/C2=C(OC)C=C(OC)C=C2OC)=O)=CC=C1OC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression. |
| In vitro activity: | TBD |
| In vivo activity: | TBD |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 25.0 | 63.38 |
The following data is based on the product molecular weight 394.438 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | TBD |
| In vitro protocol: | TBD |
| In vivo protocol: | TBD |
1: Cho SY, Cosenza SC, Pallela V, Panda G, Reddy MV, Reddy EP, Roboz J.
Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone
antineoplastic drug, in colon cancer cells using LC/MS/MS. J Pharm Biomed Anal.
2013 Mar 5;75:138-44. doi: 10.1016/j.jpba.2012.11.022. Epub 2012 Nov 23. PubMed
PMID: 23261806.
2: Nuthalapati S, Zhou Q, Guo P, Lv H, Cosenza S, Reddy MV, Reddy EP, Gallo JM.
Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer
agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor
chemotherapy. Pharm Res. 2012 Sep;29(9):2499-511. doi: 10.1007/s11095-012-0780-y.
Epub 2012 Jun 8. PubMed PMID: 22678771.
3: Park IW, Reddy MV, Reddy EP, Groopman JE. Evaluation of novel cell cycle
inhibitors in mantle cell lymphoma. Oncogene. 2007 Aug 16;26(38):5635-42. Epub
2007 Mar 19. PubMed PMID: 17369860.
